UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041624
Receipt number R000047517
Scientific Title Prospective observational study on Improvement of prognosis of Pancreatic Cancer: Early Detection Project of Pancreatic Cancer in Tsu
Date of disclosure of the study information 2020/08/31
Last modified on 2023/09/03 14:14:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective observational study on Improvement of prognosis of Pancreatic Cancer:
Early Detection Project of Pancreatic Cancer in Tsu

Acronym

PIPED-Tsu

Scientific Title

Prospective observational study on Improvement of prognosis of Pancreatic Cancer:
Early Detection Project of Pancreatic Cancer in Tsu

Scientific Title:Acronym

PIPED-Tsu

Region

Japan


Condition

Condition

pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To establish a system to efficiently pick up patients with risk factors for pancreatic cancer and to detect them at an early stage through regional medical cooperation between core hospital including Mie University Hospital and the primary care clinics in Tsu area. We will examine the number of pancreatic cancer cases (especially the number of Stage 0/I cases diagnosed) and resection cases that can be diagnosed by this method. We also evaluate the transition of the resection rate and the diagnosis rate of Stage 0/I cases.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary endpoint is the rate of patients diagnosed with pancreatic cancer, calculated with a 95% confidence interval. The diagnosis rate is the number of patients diagnosed/total number of study participants.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Adults aged 20 years or older having 2 or more points on a scoring metric for prespecified pancreatic cancer risk factors will be eligible for referral.
Prespecified risk factors and associated point scores are as follows:
1. symptoms (abdominal pain, jaundice, back pain, or weight loss): 1 point
2. newly diagnosed diabetes mellitus (type 2) or worsening of diabetes: 1 point
3. family history of PC (parent, child, or siblings, including other types of pancreatic neoplasms): 1 point
4. abnormal serum amylase level (high or low): 1 point
5. elevated serum CA19-9 level: 1 point
6. pancreatic duct dilation (>3 mm) or pancreatic cyst detected by echography test: 2 points.

Key exclusion criteria

1) Patients who cannot understand the necessity of detailed examination and follow-up due to cognitive decline etc.
2) Patients who the investigator/co-investigator determined to be inappropriate for inclusion in the study

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Reiko
Middle name
Last name Yamada

Organization

Mie University Hospital

Division name

Gastroenterology and Hepatology

Zip code

514-8507

Address

2-174, Edobashi, Tsu-city, Mie-prefecture

TEL

059-232-1111

Email

reiko-t@clin.medic.mie-u.ac.jp


Public contact

Name of contact person

1st name Reiko
Middle name
Last name Yamada

Organization

Mie University Hospital

Division name

Gastroenterology and Hepatology

Zip code

514-8507

Address

2-174, Edobashi, Tsu-city, Mie-prefecture

TEL

059-232-1111

Homepage URL


Email

reiko-t@clin.medic.mie-u.ac.jp


Sponsor or person

Institute

Mie University

Institute

Department

Personal name



Funding Source

Organization

Mie University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Mie University Hospital

Address

2-174, Edobashi, Tsu-city, Mie-prefecture

Tel

059-232-1111

Email

reiko-t@clin.medic.mie-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 08 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 04 Month 19 Day

Date of IRB

2020 Year 08 Month 31 Day

Anticipated trial start date

2020 Year 09 Month 01 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Adults aged 20 years or older having 2 or more points on a scoring metric for prespecified pancreatic cancer risk factors will be eligible for referral. If treatment is needed, start treatment such as resection. If there is some kind of lesion but follow-up is possible, follow-up observation by images and blood sampling will be continued every 6 months to 1 year at an institutional hospital in Tsu City.


Management information

Registered date

2020 Year 08 Month 31 Day

Last modified on

2023 Year 09 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047517


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name